Profile data is unavailable for this security.
About the company
Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.
- Revenue in USD (TTM)2.13m
- Net income in USD-62.01m
- Incorporated2013
- Employees99.00
- LocationTalis Biomedical Corp1100 Island Drive, Suite 101REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 433-3000
- Fax+1 (302) 636-5454
- Websitehttps://talisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibio Inc | 50.00k | -17.13m | 15.59m | 26.00 | -- | 0.6201 | -- | 311.73 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 15.81m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 16.00m | 1.00 | -- | 0.0893 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Allied Corp | 21.51k | -9.00m | 16.18m | -- | -- | -- | -- | 752.43 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -18.16m | 16.26m | 16.00 | -- | 2.25 | -- | 71.94 | -0.8641 | -0.8641 | 0.0108 | 0.2853 | 0.0085 | -- | 12.91 | 14,125.00 | -68.21 | -63.43 | -104.99 | -85.72 | -- | -- | -8,033.63 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 16.48m | 150.00 | -- | 0.5355 | -- | 0.1758 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 16.64m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Flora Growth Corp | 76.07m | -47.36m | 16.67m | 97.00 | -- | 1.81 | -- | 0.2191 | -6.62 | -7.97 | 10.04 | 0.7167 | 1.45 | 6.76 | 31.13 | 784,237.10 | -89.22 | -- | -130.91 | -- | 23.32 | -- | -61.35 | -- | 0.7897 | -- | 0.2317 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Talis Biomedical Corp | 2.13m | -62.01m | 16.69m | 99.00 | -- | 0.2415 | -- | 7.82 | -34.26 | -34.26 | 1.18 | 37.93 | 0.0162 | -- | 11.92 | 21,555.55 | -46.98 | -68.18 | -51.14 | -74.22 | 98.08 | -- | -2,905.67 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Galecto Inc | 0.00 | -30.83m | 17.08m | 13.00 | -- | 0.6066 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Tonix Pharmaceuticals Holding Corp | 7.77m | -116.66m | 17.35m | 103.00 | -- | 0.1009 | -- | 2.23 | -8.62 | -8.62 | 0.4572 | 1.80 | 0.0409 | -- | -- | 75,417.48 | -61.38 | -59.46 | -68.01 | -65.92 | 38.97 | -- | -1,501.78 | -5,126.73 | 1.81 | -- | 0.0779 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Senti Biosciences Inc | 1.28m | -86.11m | 17.39m | 48.00 | -- | 0.3097 | -- | 13.64 | -1.93 | -1.44 | 0.0285 | 1.23 | 0.0097 | -- | 2.94 | 26,562.50 | -65.33 | -- | -71.42 | -- | -- | -- | -6,753.80 | -- | -- | -- | 0.0018 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 17.67m | 2.00 | -- | 0.5676 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 17.70m | 20.00 | -- | -- | -- | 3.60 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 17.96m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Talis Biomedical Corp's reporting currency: US Dollar USD
43.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2023 | 508.32k | 27.95% |
| Greenlight Capital, Inc.as of 31 Dec 2023 | 149.05k | 8.19% |
| BML Capital Management LLCas of 31 Mar 2024 | 42.74k | 2.35% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 31.01k | 1.71% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 17.43k | 0.96% |
| Prelude Capital Management LLCas of 31 Dec 2023 | 14.93k | 0.82% |
| Geode Capital Management LLCas of 31 Dec 2023 | 11.28k | 0.62% |
| Citadel Securities LLCas of 31 Dec 2023 | 10.02k | 0.55% |
| Abaris Investment Management AGas of 30 Jun 2023 | 3.73k | 0.21% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.76k | 0.15% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
